Table 3.
Measures used to assess RA disease severity at diagnosis and during treatment, and consistency of their use
| (n = 125) | Used only at diagnosis | Used only during treatment | Used at diagnosis and during treatment | Used at any point | Correlation between use at diagnosis and during treatment | ||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | ||
| PGA | 5 | 4 | 10 | 8 | 63 | 50 | 78 | 62 | 0.759** |
| DAS28 score | 5 | 4 | 3 | 2 | 38 | 30 | 46 | 37 | 0.857** |
| RAPID3 | 7 | 6 | 3 | 2 | 31 | 25 | 41 | 33 | 0.808** |
| CDAI | 5 | 4 | 1 | 1 | 20 | 16 | 26 | 21 | 0.845** |
| Vectra biomarker score | 6 | 5 | 4 | 3 | 5 | 4 | 15 | 12 | 0.505** |
| Other* | 1 | 1 | 14 | 11 | 17 | 14 | 32 | 26 | 0.661** |
CDAI clinical disease activity index, DAS28 Disease Activity Score 28, PGA physician global assessment, RAPID3 routine assessment of patient index data 3
* Other includes: HAQ Health Assessment Questionnaire, TJC total joint count, VAS visual analog scale; CRP C-reactive protein, CBC complete blood count, PGA patient global assessment, PE, ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) remission criteria, QCRP quantitative C-reactive protein, RAPID5 routine assessment of patient index data 5, SDAI simple disease activity index, SJC swollen joint count, VASm Visual Analogic Scale during movement
** Significant at 0.01 level